Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583713 · ClinicalTrials.gov registry record · Phase 1
An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters
A Phase 1 study, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00583713 is a Phase 1 study that has completed, run by Braintree Laboratories. The registered enrollment target is 18 participants.
The verdict
NCT00583713, a Phase 1 study, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
To evaluate and compare the effects on safety measures and clinical chemistry after BLI800 in two groups of patients and one group of healthy controls. The patient groups will be those with mild or moderate hepatic impairment or moderate renal disease.
Interventions
- DRUG BLI-800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00583713
The ClinicalTrials.gov registry entry for NCT00583713 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BLI-800 is the first listed.
NCT00583713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00583713 about?
NCT00583713 is a clinical study titled "An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters". To evaluate and compare the effects on safety measures and clinical chemistry after BLI800 in two groups of patients and one group of healthy controls. The patient groups will be those with mild or moderate hepatic impairment or moderate renal disease.
What is the current status of trial NCT00583713?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-08. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00583713?
The interventions under investigation include: BLI-800 (DRUG).
Who is sponsoring clinical trial NCT00583713?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.